Coherus BioSciences (CHRS) Misses Q3 EPS by 1c, Misses on Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update
November 6, 2025 4:14 PM ESTCHS-114, a highly selective Treg depleter, clinical program expanded to include colorectal cancer
Q3 2025 ending cash, cash equivalents and marketable securities of $191.7 million
LOQTORZI® net revenue was $11.2 million, a 12% increase over Q2 2025
Conference call today at 5:00 p.m. Eastern Standard Time
REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today reported financial results for the third quarter ended September 30, 2025 and provided an overview of recent business highlights.
In Q3 2025, we gained... More
